Skip to content
Screener

ClearPoint Neuro CLPT Allowance for Doubtful Accounts Receivable (Current)

Allowance for Doubtful Accounts Receivable (Current) at other companies

Abbott logo
AbbottABT
$486M+73.6%
IAR
Integra LifeSciencesIART
$7.33M+6.9%
LivaNova logo
LivaNovaLIVN
$10.72M-16.6%
Globus Medical logo
Globus MedicalGMED
$44.37M+66.8%
BioLife Solutions logo
BioLife SolutionsBLFS
$16K-88.1%
Medtronic logo
MedtronicMDT

Other financials

Income statement

See full
Revenue$12.1M+42.9%
Gross profit$7.8M+51.1%
Operating income-$8.5M-37.6%
Net income-$9.6M-58.5%
EPS (diluted)-$0.32-45.5%

Balance sheet

See full
Cash & equivalents$36.5M+195%
Total debt$63.6M+1,750%
Total equity$18.8M-5.7%
Total assets$93.4M+211%

Cash flow

See full
Operating cash flow-$8.0M-29.1%
CapEx$645.0K+252%
Free cash flow-$8.6M-35.5%

Valuation

See full
Market cap$444.45M+48.3%
Enterprise value$471.52M+60.7%
P/S10.9×+2.0×

Profitability

See full
Gross margin62.3%+1.1pp
Operating margin-65.2%-1.9pp
Net margin-71.6%+8.8pp
FCF margin-65.7%+269pp

Returns & leverage

See full
Return on equity-149.7%+4,074pp
Debt / equity3.4×+3.2×
Current ratio5.8×+2.3×

Where this comes from

Reported directly by ClearPoint Neuro in its filing.

Tagged under the XBRL concept us-gaap:AllowanceForDoubtfulAccountsReceivable.

The source filing: ClearPoint Neuro’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 5:00 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-221890

2025 was $1.1 million and $1.2 million, respectively. The Company evaluates the historic loss experience on the accounts receivable balance and also considers separately customers with receivable balances that may be negatively impacted by current economic developments and market conditions. The estimate is a result of the Company's ongoing evaluation of collectability, customer creditworthiness, historical levels of credit losses and future expectations.

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is ClearPoint Neuro's allowance for doubtful accounts receivable (current)?
ClearPoint Neuro (CLPT) reported allowance for doubtful accounts receivable (current) of $1.1M in Q1 2026.
How has ClearPoint Neuro's allowance for doubtful accounts receivable (current) changed year-over-year?
ClearPoint Neuro's allowance for doubtful accounts receivable (current) decreased by 15.4% year-over-year, from $1.3M to $1.1M.
What is the long-term trend for ClearPoint Neuro's allowance for doubtful accounts receivable (current)?
Over 5 years (2020 to 2025), ClearPoint Neuro's allowance for doubtful accounts receivable (current) has grown at a 82.1% compound annual growth rate (CAGR), from $60K to $1.2M.
What does allowance for doubtful accounts receivable (current) mean?
This is the valuation allowance for current receivables that are considered uncollectible due to disputes, bankruptcy, or other non-payment issues. It serves as a buffer against potential losses from customer defaults. It is a critical indicator of the health of the company's accounts receivable portfolio.

Ask your AI about ClearPoint Neuro's allowance for doubtful accounts receivable (current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude